The iSBTc/SITC primer on tumor immunology and biological therapy of cancer: a summary of the 2010 program

Journal of Translational Medicine

Review

Patrick Hwu¹  Walter J Urba²  James M Balwit³  Francesco M Marincola⁴ 

[1] Department of Melanoma Medical Oncology, the University of Texas, MD Anderson Cancer Center, Houston, TX, USA;Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, OR, USA;Society for Immunotherapy of Cancer, Milwaukee, WI, USA;Society for Immunotherapy of Cancer, Milwaukee, WI, USA;Infectious Disease and Immunogenetics Section (IDIS), Dept. of Translation Medicine, Clinical Center, and Center for Human Immunology (CHI), National Institutes of Health, Bethesda, MD, USA;

关键词: Melanoma;    Tumor Microenvironment;    Arginase;    Ipilimumab;    Cancer Vaccine;   

DOI  :  10.1186/1479-5876-9-18

 received in 2011-01-17, accepted in 2011-01-31,  发布年份 2011

来源: Springer

【 摘 要 】

The Society for Immunotherapy of Cancer, SITC (formerly the International Society for Biological Therapy of Cancer, iSBTc), aims to improve cancer patient outcomes by advancing the science, development and application of biological therapy and immunotherapy. The society and its educational programs have become premier destinations for interaction and innovation in the cancer biologics community. For over a decade, the society has offered the Primer on Tumor Immunology and Biological Therapy of Cancer™ in conjunction with its Annual Scientific Meeting. This report summarizes the 2010 Primer that took place October 1, 2010 in Washington, D.C. as part of the educational offerings associated with the society's 25th anniversary. The target audience was basic and clinical investigators from academia, industry and regulatory agencies, and included clinicians, post-doctoral fellows, students, and allied health professionals. Attendees were provided a review of basic immunology and educated on the current status and most recent advances in tumor immunology and clinical/translational caner immunology. Ten prominent investigators presented on the following topics: innate immunity and inflammation; an overview of adaptive immunity; dendritic cells; tumor microenvironment; regulatory immune cells; immune monitoring; cytokines in cancer immunotherapy; immune modulating antibodies; cancer vaccines; and adoptive T cell therapy. Presentation slides, a Primer webinar and additional program information are available online on the society's website.

【 授权许可】

Unknown   
© Balwit et al; licensee BioMed Central Ltd. 2011. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.